Top Markets
Coin of the day
AIkido Pharma Inc. AIkido Pharma Inc.

AIkido Pharma Inc.

AIKI
Rang in aandelen #30001
AIkido Pharma Inc., established in 1967 and headquartered in New York, New... AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.
Aandeelprijs
$3.56
Laatst gesynchroniseerd: 2022-12-21
Marktkapitalisatie
$18.70M
Verandering (1 dag)
0.28%
Verandering (1 jaar)
0.00%
Land
US
Handel AIkido Pharma Inc. (AIKI)

Categorie

EPS voor AIkido Pharma Inc. (AIKI)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van AIkido Pharma Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van AIkido Pharma Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten